Purpose: To examine the 4-year outcomes from Carotid Revascularization using Endarterectomy or Stenting Systems (CaRESS) in light of the current reimbursement guidelines for carotid artery stenting (CAS) from the Centers for Medicare and Medicaid Services (CMS).
¤ ¤
In the US, carotid artery stenting (CAS) is emerging as a practical therapeutic alternative to carotid endarterectomy (CEA) in highrisk patients based upon device-specific clinical trials [1] [2] [3] [4] [5] [6] that led to Food and Drug Administration (FDA) approval of a number See commentary page 410 of carotid stenting systems and embolic protection devices. In 2004, after the first carotid stenting systems were approved by the FDA, the Centers for Medicare and Medicaid Services (CMS) issued a National Coverage Decision (NCD) 7 that provided reimbursement for the treatment of high-risk patients with symptomatic .70% carotid stenosis so long as they were treated with FDA-approved stents and a distal embolic protection device (EPD). Subsequently, the CMS allowed reimbursement for CAS in symptomatic high-risk patients with carotid stenosis between 50% and 69% and asymptomatic highrisk patients with stenosis .80% only if the patients were enrolled and treated in a Category B IDE (Investigational Device Evaluation) clinical trial or post-approval study. In 2007, the CMS considered expanding coverage by removing the clinical study restrictions on these high-risk subsets. 8 However, the CMS ultimately decided not to implement the proposed expansion of coverage, citing conflicting data and lack of uniform support for such changes. 9 Today, costs of treatment of symptomatic patients who do not meet the high-risk criteria and those with ,80% asymptomatic carotid stenosis are not reimbursed regardless of participation in an approved clinical trial.
The Carotid Revascularization using Endarterectomy or Stenting Systems (CaRESS) received IDE approval in 2001 as one of the few prospective multicenter clinical trials to focus on the broad-risk population of patients with symptomatic and asymptomatic carotid stenosis commonly seen in clinical practice. 10, 11 Both the 30-day and 1-year results of the CaRESS trial showed no difference in outcome between carotid CEA and CAS with distal cerebral protection: both had 2% 30-day combined stroke/death rates. 12, 13 During the 8 years since CaRESS was conceived, the techniques and devices for CAS have evolved considerably, 14 -17 yet reimbursement has remained available for only high-risk patients. Moreover, the aging population has presented new treatment challenges. [18] [19] [20] [21] [22] [23] [24] In particular, recent data suggest that octogenarians are at particularly high risk for CAS, 20, 23, 24 though various single-center experiences have reported the safety of CAS in this subgroup. 19, 21, 21, 25, 26 In this report of the 4-year outcomes of the CaRESS trial, we examine the CMS coverage guidelines for CAS in a series of subgroup analyses that stratify this large, broad-risk patient cohort by risk status, symptomatology, stenosis grade, and age .80 years.
METHODS

Study Design and Patient Population
This CaRESS study was a 14-site, 2-phase clinical trial (Appendix) designed as an equivalence cohort study to determine whether the stroke/death rate in patients treated with CAS under distal cerebral protection was comparable to patients undergoing CEA. Follow-up to 4 years was mandated for Phase I. The study design, clinical site selection, patient enrollment, treatment selection, procedural techniques, and the 30-day and 1-year results for Phase I have been published. [10] [11] [12] [13] An enrollment goal of 450 subjects (300 CEA, 150 stent) was selected to provide sufficient precision in determining a 3% event rate in the CEA arm and enough carotid stent cases to ensure comparable patients in each treatment cohort. 12 The CAS patients were treated with the Monorail Wallstent (Boston Scientific, Natick, MA, USA) and the GuardWire Plus (Medtronic CardioVascular, Santa Rosa, CA, USA) distal protection device according to their instructions for use.
Follow-up included physical examination, review of medications and adverse events, neurological examination with National Institutes of Health Stroke Scale assessment and quality of life/cerebral events questionnaires, 13 and carotid ultrasound at 1, 6, and 12 months and annually to 48 months. However, at the annual visits, only symptomatic patients had a neurological examination. Angiography was performed as needed to evaluate symptomatic patients or those with an indication of stenosis .75% on an ultrasound scan.
The primary endpoints included (1) allcause mortality, (2) any stroke, and (3) myocardial infarction (MI), as well as the composite endpoints of (4) death/any nonfatal stroke and (5) death/nonfatal stroke/MI. The secondary endpoints were restenosis ($75% narrowing documented by ultrasonography or symptomatic narrowing .50% that required secondary treatment), repeat angiography, and carotid revascularization.
Of the 439 patients enrolled in CaRESS, 397 patients (247 men; mean age 71 years, range 44-89) were treated with carotid endarterectomy (n5254) or protected CAS (n5143). The demographics, clinical status, and past medical history of the treatment groups have been published. 12, 13 More than 90% of patients had .75% stenosis; about two thirds were asymptomatic. There were no significant differences in baseline patient characteristics between the treatment groups with the exception of a more frequent history of prior CEA (30% CAS versus 11% for CEA, p,0.0001) and prior carotid stent placement in the CAS group (6% versus 0% for CEA, p50.0002). In both groups, the etiology was atherosclerosis in the majority of cases (87% in CEA and 76% in CAS); CAS was performed for restenosis in 17% and post-radiation stenosis in 4%.
Patient Stratification
To complement the 4-year outcome data for the entire CaRESS cohort, additional analyses were performed to compare outcomes according to gender, risk classification, symptom status, stenosis grade, and age .80 years. Risk was dichotomized based on published CMS criteria for carotid stenting, 9 which differed somewhat from the definition used in CaRESS (Table 1 ). According to the CMS, patients with one or more of the following were considered to be high risk: age $80 years, New York Heart Association class III/IV for congestive heart failure, Canadian Cardiovascular Society class III/IV, left ventricular ejection fraction ,30%, unstable angina, previous MI, end-stage renal disease on dialysis, severe pulmonary disease, previous CEA with recurrent stenosis, prior radiation treatment to the neck, tracheostomy, high cervical internal carotid artery lesion, common carotid artery lesion below the clavicle, contralateral carotid occlusion, and contralateral laryngeal nerve palsy. Of the 397 CaRESS patients, 184 (46%) were classified as ''high risk'' and 213 (54%) were classified as ''non-high risk'' according to this CMS definition.
Patients were classified as symptomatic if one or more of the following symptoms were present within the 6 months prior to enrollment: transient ischemic attack (TIA; distinct focal neurological dysfunction persisting ,24 hours), focal cerebral ischemia producing a non-disabling stroke (modified Rankin scale ,3 with symptoms for $24 hours), or amaurosis fugax. Based on these criteria, 128 (32%) of the CaRESS patients were symptomatic and 269 (68%) were asymptomatic.
The baseline degree of stenosis was determined by preoperative ultrasound, with $75% diameter reduction representing severe stenosis. For purposes of this analysis, this threshold was considered equivalent to the 80% stenosis guideline used by the CMS for asymptomatic patients. Each patient in the CaRESS trial was then retrospectively assigned to 1 of 4 groups based on CMS guidelines: (1) high risk, symptomatic, $75% stenosis (n539, 10%); (2) high risk, symptomatic, 50% to 74% stenosis (n512, 3%); (3) high risk, asymptomatic, $75% stenosis (n5133, 34%); or (4) non-high risk, asymptomatic, ,75% (n5213, 54%).
Statistical Analysis
Baseline characteristics of the CEA and CAS patient groups were compared using the Student t test for continuous variables and the chi-square or Fisher exact test for categorical data. Multivariable regression analysis using the Cox proportional hazards model was performed to identify baseline factors predictive of the outcomes at 4 years for the high-risk cohort; variables with p,0.2 from the univariate analyses were entered into the model. Kaplan-Meier estimates of freedom from events for the primary and secondary endpoints were determined; the log-rank test was used to compare group event rates. Differences were considered significant if p,0.05. Statistical analyses were performed by the New England Research Institutes, Inc, using SAS statistical software (SAS Institute Inc, Cary, NC, USA).
RESULTS
Entire CaRESS Cohort
No significant differences in the primary outcome measures were found between the CEA and CAS patient groups in the 4-year analysis ( Table 2 ). All-cause mortality was 21.2% in the CEA arm and 18.7% in the CAS arm (Table 3 , p50.835). It is interesting that the CAS arm began to show higher mortality compared with CEA at 1-2 years and 2-3 years, but rebounded at 3-4 years, though there were no significant differences in survival at that time.
The incidence of any stroke at 4 years was 9.6% for CEA and 8.6% for CAS (p50.444); when combined with death, the composite rates were 26.5% for CEA versus 21.8% for CAS (Table 3 ), though this difference was not statistically significant (p50.361). The composite endpoint of death/nonfatal stroke/MI at 4 years was 27.0% in CEA versus 21.7% in CAS (Table 3, showed a trend toward better outcomes in the CAS arm, but the difference was not statistically significant. The secondary endpoints at 4 years were, in general, higher in the CAS arm, notably for the frequency of restenosis (14.7% versus 5.9% for CEA; p50.014) and repeat angiography (11.2% versus 5.1%; p50.052). A higher proportion of CAS patients had carotid reinterventions (5.6% versus 2.8% for CEA), but the difference was not statistically significant (p50.263).
Stratification
Risk status. Nearly half (184, 46%) of the CaRESS patients met at least one of the CMSdefined criteria of high risk for surgery: 107 (42%) of the 254 patients in the CEA arm and 77 (54%) of the 143 CAS patients. Baseline demographics and characteristics of the highrisk patients (Table 4 ) differed between the arms in age only; CEA patients were 3 years older than high-risk CAS patients (76 versus 73 years, p,0.05), but there were no significant differences in medical comorbidity rates. CAS patients were more likely to have carotid stenosis .75% (p50.02) and were more likely to have had a prior carotid endarterectomy (p,0.001) or carotid stent (p50.03) with restenosis from these procedures (p,0.001). CAS patients also were more likely to have peripheral vascular disease (p50.016). Table 5 demonstrates outcomes by risk level, symptom status, and age for each treatment group. There was no significant difference between the 4-year death/stroke rate between high-risk CEA (30.1%) and highrisk CAS patients (29.1%, p50.820). Similarly, there were no differences in all-cause mortality or combined death/stroke/MI rates between the high-risk patient subgroups. Adjustment for statistically significant differences at baseline, such as age, gender, stenosis $75%, etiology, history of TIA, history of stroke, congestive heart failure, and history of prior CEA/CAS, did not alter the primary outcome measures at 4 years (data not shown). The 4-year death/stroke rate among the non-highrisk group was higher among patients treated with CEA (24.1%) than patients treated with CAS (12.7%), though this result was not statistically significant (p50.104). As expected, the Kaplan-Meier event rates in the high-risk patients were in general higher than the event rates for the non-high-risk CaRESS. Symptom status. A third (32%) of patients in the CaRESS trial were symptomatic, including 84 CEA and 44 CAS patients. There was no difference in the 30-day death/stroke rate in symptomatic patients between the CEA (7.2%) and CAS (4.7%) arms (Table 5) . However, at 4 years, in symptomatic patients, the death/ stroke rate in the CEA subgroup (33.5%) was ¤ ¤ Gender. There were 161 men and 93 women in the CEA arm and 86 men and 57 women in the CAS cohort. There was only 1 death at 30 days: a woman from the CEA group. In late follow-up, 13/93 women and 26/161 men in the CEA arm died, which did not differ significantly from the 6/57 women and 17/86 men in the CAS arm who died (results not shown).
¤ ¤
Age. Patients 80 years of age and older comprised 19% of the CaRESS population: 52 (20%) of the 254 CEA patients and 25 (17%) of the 143 CAS patients. All-cause mortality at 4 years for octogenarian CEA patients (26.8%) was not statistically different from octogenarian CAS patients (41.7%, p50.158). At 4 years, the combined death/stroke rate for octogenarians treated with CEA (35.4%) was not significantly different from the death/stroke rate for octogenarians treated with CAS (54.1%, p50.204). There was no difference in overall mortality between non-octogenarian CEA patients (20.0%) and CAS patients ¤ ¤ (13.3%, p50.246). However, non-octogenarians treated with CAS rather than CEA had nearly half the incidence of combined death/ stroke (HR50.55). The death/stroke rate among non-octogenarians treated with CEA was 24.6%, while this rate was 13.8% among CAS patients (p50.049). For CEA patients, the 30-day death/stroke rate for octogenarians (4.2%) was not different from CEA patients ,80 years of age (3.5%; Table 5 ). Similarly, for CAS patients, the 30-day death/stroke rate for octogenarians (4.0%) was not different from CAS patients ,80 years of age (1.7%).
Stratification by CMS Guidelines
High risk, symptomatic, $75% stenosis (currently reimbursed by CMS). Patients in this category comprised 10% of the CaRESS trial population, including 22 patients in the CEA and 17 patients in the CAS group. There was no difference in the 30-day death/stroke rates between CEA 0.0% and CAS 5.9% (Table 6 ) and no difference in the 4-year death/stroke rate between the groups (CEA 25.3% versus CAS 12.6%, p50.444).
High risk, symptomatic, 50% to 74% stenosis and high risk, asymptomatic, stenosis $75% (reimbursed by CMS under clinical trial criteria). Because only 3% of the CaRESS trial population fell into the high risk, symptomatic, 50% to 74% stenosis group (11 CEA patients and 1 CAS patient), this group was combined with the 33% of CaRESS patients who were in the high risk, asymptomatic, $75% stenosis cohort (74 CEA patients and 59 ¤ ¤ CAS patients). There was no difference in death/stroke rates between CEA (3.6%) and CAS (1.7%) at 30 days or at 4 years (CEA 31.5% and CAS 33.5%).
Non-high risk, asymptomatic, ,75% stenosis. Of the 213 (54%) patients in this group, 147 were CEA patients and 66 were CAS patients. There were no differences in 30-day or 4-year death/stroke rates.
DISCUSSION
The CaRESS trial is unique in that it is the only prospective multicenter trial comparing CEA to CAS with distal cerebral protection in a broad-risk category of patients with carotid stenosis, representative of standard clinical practice. The overall trial results demonstrate equivalence between the procedures out to 4 years, with no differences in the all-cause mortality, stroke, or combined death/stroke endpoints at 30 days or at 4 years. Analyzing the high-risk patients alone revealed no statistically significant differences in primary outcome measures.
The outcomes in CaRESS compare favorably with the published results in high-risk carotid stent registries using distal protection. [1] [2] [3] [4] [5] [6] Although the CaRESS trial likely reflects more accurately the true decisionmaking process when treating patients with carotid stenosis, the results of the randomized, prospective Carotid Revascularization Endarterectomy versus Stent Trial (CREST) trial are anxiously anticipated to provide needed level I proof to support the selection of CEA or CAS for these patients. In the interim, the midterm results were published from two other trials designed to test the hypothesis that CAS is not inferior to CEA for treating patients with severe symptomatic carotid artery stenosis. The Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial 27 concluded after 4 years that CAS was as effective as CEA for midterm prevention of ipsilateral stroke, but CAS had a higher periprocedural risk of any stroke. At the same time, the 2-year results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial 28 found no differences between the CAS and CEA groups in the rates of ipsilateral ischemic strokes up to 2 years or of any periprocedural stroke or death.
At nearly the same time, several metaanalyses were published to examine a variety of outcomes for CAS versus CEA. [29] [30] [31] [32] [33] Murad et al. 29 used a random-effects meta-analysis to evaluate the death, stroke (disabling and non-disabling), and nonfatal MI rates at 30 days in 10 randomized controlled trials representing 3182 patients. They based equivalency of the 2 procedures on an absolute difference in events of ,2%. They found moderate-quality evidence for equivalence with respect to death and nonfatal MI, but only low-quality evidence of equivalence in stroke. Brahmanandam et al. 30 likewise looked at the differences in risk of stroke or death at 30 days in 10 trials (n53580). They found that CAS patients overall had a higher risk of 30-day stroke/death (RR 1.30 versus CEA), which was evident in trials enrolling only symptomatic patients (RR 1.63) but not in trials including both symptomatic and asymptomatic patients (RR 0.89). Using random-and fixed-effects meta-analyses of 9 trials (n53138), Jeng et al. 31 found no differences for stroke, death, or MI in the randomeffects models, but there were significantly higher 30-day event rates after CAS for death or any stroke by the fixed effects model. From these data, they concluded that CAS was not safer than surgery nor associated with a better short-term outcome. Ringleb et al. 32 drew much the same conclusions after updating their earlier analysis to include 8 trials (n52985).
The 30-day and 4-year outcomes in CaRESS clearly show that CAS is not inferior to CEA in terms of the death/stroke/MI rates for the entire cohort and for all subgroups analyzed. In fact, though the differences were not statistically significant, rates for CAS were slightly better in nearly all comparisons except restenosis rate and advanced age. This is in contrast to the initial analysis from the Society for Vascular Surgery's (SVS) Vascular Registry (VR) of more than 6400 patients. 34 Their 30-day data favored CEA in nearly every outcome measure, including the combined stroke/death/MI endpoint (2.63% versus 5.72% for CAS, p,0.001). Notably, more of the registry's CAS patients were symptomatic (49% versus 42% for CEA, p,0.001), which is not only different from the CaRESS cohort (,30% in both arms) but also other comparative studies. [1] [2] [3] [4] [5] [6] The CAS patients also had significantly more cardiovascular and cerebrovascular comorbidities, which likely account for the significant differences in the death (p50.004) and MI (p50.003) endpoints. There are notable differences between this registry, with its lack of inclusion/exclusion criteria, predefined surveillance protocol, complete follow-up data, and adjudication, and the many observational and controlled clinical trials comparing the two methods of carotid revascularization. Particularly worrisome are the self-reporting biases typical of any registry. On the other hand, this voluntary registry has an order of magnitude more patients than CaRESS, albeit from a diverse group of centers with no defined participation standards.
It is interesting that one of the only statistically significant differences in the Ca-RESS study was found in the 4-year composite endpoints of death/stroke (25% CEA versus 14% CAS, p50.049) and death/stroke/MI (25% CEA versus 14% CAS, p50.030) in patients ,80 years old, a subgroup analysis that the SVS VR did not explore. This observation in the CaRESS patients may have been due to clopidogrel treatment in the CAS group (CEA patients were not specifically treated with clopidogrel). This treatment to prevent MI may be more important in the younger (,80) age group than in the patients .80 years. While octogenarians experienced higher allcause mortality in the CAS arm compared with open surgery, the difference was not statistically significant, perhaps due to other factors associated with this age category, such as vessel tortuosity, arch elongation, and calcification.
Of special note, our analysis of the CaRESS database found no significant differences in outcomes when patients were categorized according to CMS reimbursement categories (risk class, symptom status, or stenosis grade). This observation becomes particularly significant when one considers that only 10% of patients treated in CaRESS would have been eligible for reimbursement using current CMS guidelines. If CMS were to expand ¤ ¤ 
Limitations
The study had the major limitation inherent to any observational cohort study, namely, lack of randomization. Further, there is a potential for type II error with post hoc statistical comparisons between small subgroups with low expected event rates. These subanalyses are potentially underpowered to determine real differences, so caution should be advised regarding statements of observed differences in outcomes between CEA and CAS for the small subgroup comparisons. Further, most of the patients in the study were asymptomatic, but this is common among comparative carotid revascularization trials.
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Conclusion
The 4-year results of the CaRESS trial suggested that the risk of death or stroke following CAS using distal protection is equivalent to endarterectomy in a broad-category population with carotid stenosis. There did not appear to be any differences in mortality between treatment arms when comparing high-risk with non-high-risk patients. After 4 years, carotid stenting had a 2-fold higher restenosis rate compared to CEA. It is expected that as further evidence is collected and published, the CMS guidelines will also be expanded to reflect a broader population.
